In addition, the greater increase in TRIB3 expression via gossypol treatment in BxPC-3 cells than that in MIA PaCa-2 cells may not only correlate with higher toxicity, but could also result in a better therapeutic effect against pancreatic cancer cells containing wild-type KRAS. The gene discussed is TRIB3; the disease is familial pancreatic carcinoma.